Theravance Biopharma to Participate in Upcoming Investor Conferences

Core Insights - Theravance Biopharma, Inc. will participate in two investor conferences in December 2025, focusing on healthcare and rare diseases [1][2] Group 1: Upcoming Events - The company will present at the 8th Annual Evercore Healthcare Conference on December 4, 2025, in a fireside chat format from 8:20 to 8:40 AM ET [1] - Theravance will also participate in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, with a panel discussion scheduled from 2:15 to 2:45 PM ET [1] - One-on-one meetings will be available for interested investors during both events [1] Group 2: Company Overview - Theravance Biopharma focuses on delivering impactful medicines, leveraging decades of expertise [3] - The company has developed YUPELRI (revefenacin), an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD) [3] - Ampreloxetine, a late-stage investigational drug for neurogenic orthostatic hypotension in patients with Multiple System Atrophy, is being developed as a potential first-in-class therapy [3]